MHMuhammad Zain Ul Haq

Muhammad Zain Ul Haq

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Zain Ul Haq has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Umbilical port versus epigastric port for gallbladder extraction in laparoscopic cholecystectomy. An updated systematic review and meta-analysis

    by Saad Ashraf, Muhammad Zain Ul Haq, Muhammad Burhan, Ayesha Shaukat, Muhammad Ahsan Ansari, Muhammad Shahmeer Ullah Shah, Khadija Jameel, Omar Abdullah Gill, Muhammad Hamza Khan, Biruk Demisse Ayalew, et al.

  • Open Access

    Reduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression

    by Ayesha Shaukat, Saad Ashraf, Hamza Irfan, Muhammad Shahmeer Ullah Shah, Yumna Khabir, Santosh Sah, Um E. Abiha Batool, Muhammad Zain Ul Haq, Omer Bin Khalid Jamil, Aymar Akilimali

    Background: Reduced‐port laparoscopic colectomy (RPLC) has emerged as an alternative to multi‐port laparoscopic colectomy (MPLC) for colorectal cancer surgery, aiming to reduce operative morbidity and improve cosmetic outcomes. This systematic review and meta‐analysis evaluated and compared operative, postoperative, and oncologic outcomes between RPLC and MPLC. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to June 2025. The protocol was registered on PROSPERO (CRD420251078328). Included studies were randomized controlled trials (RCTs) or cohort studies comparing RPLC and MPLC. Primary outcomes were estimated blood loss, operative time, hospital stay, lymph node yield, and postoperative recovery indicators. Secondary outcomes included conversion rates, complications, and Clavien‐Dindo graded adverse events. Risk of bias was evaluated using the Newcastle‐Ottawa Scale and Cochrane RoB 2.0 tool. A random‐effects meta‐regression was performed to explore the impact of high‐stage tumors on the outcomes. Results: Thirteen studies ( n = 2897) were included. RPLC significantly reduced operative time (MD: −19.98 min; 95% CI: −29.73 to −10.24, p < 0.0001) and estimated blood loss (MD: −13.70 mL; 95% CI: −25.63 to −1.77, p = 0.02) without compromising hospital stay, lymph node yield, or complication rates. Meta‐regression revealed tumor stage significantly influenced operative time ( p = 0.0013). Conclusions: RPLC appears to provide comparable postoperative outcomes to MPLC with modest intraoperative advantages. As the evidence is largely retrospective and heterogeneous, these findings indicate the feasibility of RPLC rather than its superiority over MPLC. High‐quality clinical trials with longer follow‐up are required to confirm these findings and optimize clinical decision‐making. Trial Registration: PROSPERO registration ID: CRD420251078328


  • Open Access

    Safety and Efficacy of Eslicarbazepine Acetate in Children Diagnosed With a Focal Seizure Disorder: A Systematic Review and Meta‐Analysis

    by Neha Bhagwan Das, Muhammad Zain Ul Haq, Eiman Anwar, Manav Das, Ariba Asif, Umaimah Naeem, Mohammad Mohsin Khan, Mahrukh Arshad, Saima Javed, Aymar Akilimali

    Background: Epilepsy can have a negative impact on cognitive and social functioning. Eslicarbazepine acetate (ESL) is used to treat focal seizures, although its safety and efficacy, particularly as an additional treatment, warrant more study. The purpose of this study was to evaluate the safety and efficacy of ESL in children with focal seizures by analyzing data from relevant clinical trials. Methods: This study was conducted in line with the PRISMA guidelines and has been registered on the PROSPERO 2024 CRD42024569119 register. A detailed search up to July 2024 through Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar was conducted for the studies comparing ESL with placebo. For the meta‐analysis, the Mantel–Haenszel random‐effects model was applied, and heterogeneity was measured using the I 2 index. Results: The study included a total of 742 children from the randomized controlled trials; of these, 414 were given ESL, whereas 328 were given a placebo. ESL significantly reduced seizure frequency when compared to placebo (SMD = −0.29; 95% CI [−0.57, −0.02]). Nevertheless, it has been related to a greater risk of side effects, including headaches, sleepiness, nausea, vomiting, double vision, and dizziness. Adverse events were measured to evaluate clinical significance. Treatment‐emergent‐related adverse events (TEAEs) occurred in 52.2% of ESL‐treated participants versus 49.1% in placebo individuals (RR = 1.08; 95% CI [0.96–1.20]; p = 0.20), indicating no statistically significant increase overall. However, specific adverse events were significantly more common with ESL, including somnolence: RR = 1.95; 95% CI (1.11–3.43); p = 0.02 and diplopia: RR = 4.34; 95% CI (1.60–11.78); p = 0.004. Other common but nonsignificant adverse events included headache (11.49%), vomiting (6.15%), nausea (3.34%), and dizziness (3.2%). Adverse event‐related treatment discontinuation was reported in 5.2%–5.9% of ESL patients compared to 2.3%–2.5% of placebo patients. Most adverse events were mild to severe, although serious adverse events (e.g., status epilepticus, device‐related problems) were more common in the ESL group. Conclusion: Though ESL increases the risk of adverse effects, it dramatically reduces seizure frequency in children with focal epilepsy. These risks require regular monitoring. Subsequent study should focus on long‐term effectiveness, safety, and ways to mitigate the negative effects of ESL.

  • Open Access

    Efficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials

    by Muhammad Zain Ul Haq, Saad Ashraf, Muhammad Shahmeer Ullah Shah, Samia Aziz Sulaiman, Ayesha Shaukat, Muhammad Ahsan Ansari, Areeba Aamir Ali Basaria, Laveeza Fatima, Humza Saeed, Aman Goyal, et al.

    Introduction: Since late 2019, COVID-19 has had a catastrophic impact on public health. Ensitrelvir, a new antiviral targeting the SARS-CoV-2 main protease, has reduced viral replication and disease severity. This meta-analysis and systematic review assessed Ensitrelvir’s efficacy and safety in patients with mild-to-moderate COVID-19 symptoms. Methods: A comprehensive search was conducted in PubMed (Medline), Scopus, Embase, and CENTRAL up to July 2024 to retrieve randomized controlled trials (RCTs) comparing Ensitrelvir to placebo in adults with mild to moderate, RT-PCR–confirmed COVID-19. Outcomes were assessed at standardized time points, with viral RNA measured at day 4. Mean differences (MD) for continuous outcomes and risk ratios (RR) for binary outcomes, both with 95% confidence intervals (CIs), were calculated using the Mantel–Haenszel random-effects model. Efficacy outcomes included SARS-CoV-2 viral RNA, while safety outcomes included HDL, triglycerides, bilirubin, AST, headache, diarrhea, TEAEs, TRAEs, serious TEAEs, and treatment discontinuation. The quality of the included RCTs was assessed with the Cochrane Risk of Bias 2 (ROB2) tool. Results: The analysis included six RCTs with 2,793 participants: 1,860 received Ensitrelvir and 933 were given a placebo. Ensitrelvir gave significant results for reduced viral RNA levels of SARS-CoV-2 [MD: − 1.35; 95% CI − 1.58 to − 1.13; p < 0.01] and the incidence of lower cholesterol levels [RR: 8.83; 95% CI 4.05 to 19.27; p < 0.01] compared to the placebo group. However, it was associated with increased risks of decreased HDL levels, elevated triglycerides, increased bilirubin, more headaches, and a higher overall occurrence of treatment-emergent adverse events. Conclusion: Ensitrelvir effectively reduces viral load in COVID-19 patients, but its safety profile raises concerns due to significant adverse effects. The benefits must be carefully weighed against the risks, and further research is needed to confirm its role in treatment and to find ways to mitigate these adverse effects.


  • Open Access

    Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis

    by Muhammad Zain Ul Haq, Hamza Irfan, Muhammad Shahmeer Ullah Shah, Anusha Sumbal, Sanila Mughal, Saad Ashraf, Areeba Aamir Ali Basaria, Abdullah, Muhammad Aaqib Chacho, Biruk Demisse Ayalew


  • Open Access

    Comments on: “Pain Lateralization in Cluster Headache and Associated Clinical Factors”

    by Sabika Kazmi, Maham Iqbal, Muhammad Zain Ui Haq

    Kazmi S, et al. J Clin Neurol. 2025 Sep;21(5):474-475. https://doi.org/10.3988/jcn.2025.0254